MBI gears up for Phase II trials of FSO69:
This article was originally published in Clinica
Executive Summary
Molecular Biosystems (US) plans to begin Phase II trials of its organ perfusion ultrasound contrast agent, FSO69, in the autumn following the successful completion of Phase I trials. Left ventricular border enhancement and myocardial perfusion were observed in all subjects in the initial trial, says MBI. Safety of the second generation agent has been demonstrated, says chairman and CEO Kenneth Widder. "Future clinical studies will be performed to verify efficacy in the liver and kidneys."